Recent studies revealed that sirtuin 1 (SIRT1) is involved in the regulation of energy metabolism and its agonist resveratrol showed anti-obesity effect. This study aims to determine whether BTM-0512, a novel derivative of resveratrol, acts as an antagonist of obesity and to explore its possible mechanisms. High-fat diet (HFD)-induced obese mice were intragastrically administered with BTM-0512 (5, 10, and 20 mg/kg/day) or resveratrol (10 mg/kg/day). It was found that the body weight, Lee's index, ratio of visceral adipose tissue (VAT) to body weight, and blood glucose were significantly reduced in BTM-0512-treated mice when compared with those in mice treated with resveratrol. BTM-0512 up-regulated the expressions of SIRT1, full length PRDM16 (fPRDM16), total PRDM16 (tPRDM16, including fPPRDM16 and other PRDM16 isoforms), and uncoupling protein 1 (UCP1) in both brown and subcutaneous adipose tissues. Although BTM-0512 and resveratrol also up-regulated SIRT1 and tPRDM16 levels in VAT of HFD-induced obese mice, the expressions of fPRDM16, UCP1, and TMEM26 were down-regulated. In mouse primary subcutaneous preadipocytes cultured with or without adipogenic medium, BTM-0512 up-regulated fPRDM16, tPRDM16, and UCP1 expressions, which was reversed by SIRT1 antagonists. But in cultured brown and visceral adipocytes, the UCP1 protein level showed no significant change after treatment with 1 μM of BTM-0512. Moreover, transfection with human SIRT1 plasmid reduced lipid deposit, as well as the mRNA levels of fPRDM16, UCP1, and TMEM26, in cultured human visceral adipose-derived stem cells. In conclusion, BTM-0512 has stronger anti-obesity effect than resveratrol, which might be associated with activation of beige remodeling in subcutaneous adipose tissue.
Introduction
Obesity, occurring due to a sustained imbalance between caloric intake and energy expenditure, is a global health problem. There are two kinds of adipose tissues: white adipose tissue (WAT) serving as an energy storage organ [1] , and brown adipose tissue (BAT) causing energy expenditure via uncoupling protein 1 (UCP1)-induced thermogenesis. Therefore, promotion of BAT formation is expected to be a promising new anti-obesity strategy [2, 3] .
Sirtuin 1 (SIRT1) is an NAD-dependent protein deacetylase, which has been proved to function as a key metabolic sensor in various tissues [4, 5] . Accumulating evidence suggests that SIRT1 is a key metabolic sensor to control the metabolism of glucose and lipids [6] . In addition to blocking the differentiation of white adipocytes, SIRT1 is also involved in the formation of BAT and can prevent metabolic diseases [7, 8] . For example, over-expression of SIRT1 results in down-regulation of WAT-specific genes and up-regulation of BATspecific genes in subcutaneous adipose tissue (SAT) [9] .
Accumulating evidence shows that SIRT1 activators can mimic the effects of SIRT1 on energy metabolism. Resveratrol (trans-3, 5, 4′-trihydroxystilbene) is a well-recognized activator of SIRT1. It exerts lipid-lowering function and calorie-restriction effects. In high-fat diet (HFD)-fed mice, resveratrol was demonstrated to have an anti-obesity effect [10] [11] [12] [13] . Recent evidence showed that resveratrol induced brown-like adipocyte (beige adipocytes) formation in inguinal SAT via AMPKα1 activation, suggesting that its beneficial anti-obesity effects might be partly due to the beige remodeling of SAT [14] .
However, resveratrol is poorly absorbed and easily oxidized, which limits its clinical application. Recently, a series of resveratrol derivatives have been developed and some of them show stronger activities than resveratrol in some aspects [15] . To increase the potency, the structure of resveratrol was modified, and a novel methylated derivative, 3,5,4′-trimethoxystilbene (BTM-0512), was obtained ( Fig. 1) [16] . Compared with resveratrol, BTM-0512 is more stable, the oral absorption of BTM-0512 is improved and its half-life is extended. Moreover, previous studies have revealed that BTM-0512 is easily accumulated in the liver and adipose tissues, and the concentration of BTM-0512 in adipose tissue is much higher than that in plasma [16, 17] . But the role of BTM-0512 in the differentiation of adipocytes as well as in the treatment of obesity remains unknown. The major aim of this study is to investigate the antiobesity effects of BTM-012 in HFD-induced obese mice and validate whether its effects are mechanistically associated with promoting brown/beige adipose formation in vivo and in vitro.
Materials and Methods

Materials
Primary antibodies, including anti-PRDM16 (No. Ab106410), anti-SIRT1 (No. Ab32441), anti-CD44 (No. Ab41478), anti-CD34 (No. Ab81289), and anti-HLA-DR (No. Ab8094) antibodies were purchased from Abcam (Cambridge, UK). Anti-UCP1 antibody (No. Sc-6529) and the secondary antibodies were from Santa Cruz Biotech (Santa Cruz, USA). All polymerase chain reaction (PCR) primers were supplied by Sango Biotech (Shanghai, China). Trizol, PrimeScript RT reagent, and One-Step SYBR PrimeScript PCR kit were obtained from TaKaRa (Dalian, China). Resveratrol was from Sigma-Aldrich (St Louis, USA ) and BTM-0512 was obtained from Xiangya School of Pharmaceutical Sciences (Changsha, China). Dexamethasone, insulin, and 3-isobutyl-1-methylxanthine (IBMX) were purchased from Sigma-Aldrich. BCA protein assay kit was from Beyotime (Shanghai, China) and Protein extraction kit was from APPLYGEN (Beijing, China).
Animal experiments
Seven-week-old male C57BL/6J mice (from the Laboratory Animal Center of Central South University, Changsha, China) were housed in an air-conditioned room at 24 ± 2°C under controlled lighting conditions (12/12 h, light/dark cycle) and acclimatized for 7 days on a standard diet purchased from the Laboratory Animal Center of Central South University. Then, the mice were randomly divided into two groups: control group (fed with standard diet, n = 18) and HFD group (fed with 67.5% standard diet, 10% milk powder, 10% lard, 2% cholesterol, 10% sucrose, and 0.5% pig bile salt for 8 weeks, n = 90). Body weight was measured every week. Eight weeks later, the HFD mice were treated with BTM-0512 (5, 10, or 20 mg/kg/per day, intragastrically) or resveratrol (positive control, 10 mg/kg/per day, intragastrically) for 2, 4, and 6 weeks, respectively. At the end of each time point, mice were fasted overnight and then anesthetized with 4% chloral hydrate (10 ml/kg, i.p.). Blood glucose was measured with 3-Nod glucometer (Shenzhen, China), and some obesity-related parameters including body weight, the Lee's index, and the ratio of visceral adipose tissue (VAT) (perirenal plus gonadal adipose tissues) weight to body weight were measured and calculated. The Lee's index was calculated as follows: Lee's index = [body weight (g) × 1000] 1/3 /length (cm). The ratio of VAT weight to body weight was calculated as follows: ratio = VAT mass (g)/body weight (g) × 100%. Inguinal SAT and scapular BAT were also collected. All animal experiments were in compliance with the 'Guide for the Care and Use of Laboratory Animals' (NIH Publication, 8th edition, 2011) and approved by the Animal Care and Use Committee of Central South University.
Immunohistochemical staining
In the Immunohistochemical staining, VATs were routinely fixed and embedded, and serially sectioned at 5 µm. Tissue sections were incubated with anti-SIRT1, anti-PRDM16 primary antibodies overnight, and then incubated with secondary antibodies at 37°C for 1 h. The positive cells were stained with Diaminobenzidine kit (Thermo Fisher Scientific, Waltham, USA) and then calculated as previously reported [18] .
Cell culture
With the approval of the Ethics Committee of Central South University, preadipocytes were isolated from inguinal (subcutaneous), omental (visceral), and interscapular (brown) adipose tissues of male C57BL/6J mice, and from human perirenal adipose tissues, respectively, as previously reported [19] . Undifferentiated preadipocytes were cultured in normal Dulbecco's modified Eagle's medium (DMEM) medium. When cells grew to~90% confluence, differentiation was induced with adipogenic medium (DMEM medium containing 10% fetal bovine serum, 1 μM dexamethasone, 0.5 mM IBMX, and 10 μg/ml insulin) for 2 days, and then cultured continuously in normal DMEM medium for 12 days. In addition to treatment with BTM-0512, SIRT1 inhibitor nicotinamide (NAM) or EX-527 was also used to confirm whether the effects of BTM-0512 were mediated by SIRT1. Human perirenal adipose tissues were harvested from kidney stone patients who signed the written consent form and met the criteria of BMI (18.5-23.9 kg/m 2 ), without hypertension, hyperlipidemia, diabetes, pituitary disease, thyroid disease, Cushing's syndrome, polycystic ovary syndrome, or other metabolic diseases. Human visceral adipose-derived stem cells (hVADSCs) were isolated as previously reported [20] , and confirmed by detecting the cell surface marker of CD44, CD34, and HLA-DR by flow cytometry. The hSIRT1-GV208 plasmid was constructed and transfected into hVADSCs (MOI = 20), and then adipogenic differentiation was induced. Oil Red O staining was used to identify lipid deposit.
Real-time PCR
RNA was extracted from subcutaneous, visceral, and brown adipose of C57BL/6J mice, as well as cultured adipocytes. Total RNA (0.5 µg) was reversely transcribed in 10 µl reaction mixture. There are several isoforms of PRDM16 (PR/SET domain 16) after mRNA alternative splicing, including full length PRDM16 (marked as fPRDM16) and short length PRDM16 (sPRDM16). In order to examine them, two primers targeting at different sites of PRDM16 were used as reported in the literature [21] with some modifications. The information of all primers was presented in Table 1 . The reactions were performed in a volume of 10 µl using the 7300 Real-time PCR Systems (Applied Biosystems, Foster City, USA) according to the following procedure: an initial denaturation step at 95°C for 30 s plus 40 cycles of the amplification steps (denaturation at 95°C for 5 s, annealing and extension at 60°C for 31 s). Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was used as a control.
Western blot analysis
Western blot analysis was carried out using standard technique. Briefly, samples containing 20 μg of protein were subject to 10% sodium dodecyl sulfate-polyacrylamide gel electrophoresis, and then the protein was electrotransfered to polyvinylidene fluoride membranes (Millipore, Billerica, USA). The membrane was blocked with 5% nonfat milk for 1 h, and then incubated with primary antibody (dilution of SIRT1 antibody was 1:500, UCP1 antibody was 1: 200) overnight at 4°C. After three times of wash with Tris Buffered Saline with Tween-20 buffer, the membrane was hybridized with the secondary antibody for 1 h at room temperature. Histone H2B or β-actin served as a control.
Statistical analysis
Results were presented as the mean ± SD and analyzed with SPSS 18.0 software. If the data met the Homogeneity Test of Variance, ANOVA analysis was used to compare among multiple groups, and Student's t-test was used to compare between two groups. Otherwise, non-parametric test was used. P < 0.05 was considered as statistically significant.
Results
Anti-obesity effects of BTM-0512 on mice fed with HFD
To induce obesity, C57BL/6J mice were fed with HFD for 8 weeks, and body weight was measured every week. Results showed that body weight in HFD group was increased in a time-dependent manner ( Fig. 2A) . Administration of BTM-0512 (5, 10, or 20 mg/kg intragastrically) showed significant time-and dose-dependent antiobesity effects, as determined by the changes of body weight (Fig. 2B ), Lee's index (Fig. 2C) , and the ratio of VAT to body weight (Fig. 2D) . After 6 weeks of treatment, the anti-obesity effect of BTM-0512 was much stronger than that of resveratrol at the same dose (10 mg/kg intragastrically). Moreover, the levels of blood glucose were also significantly decreased in HFD mice treated with BTM-0512 (Fig. 2E) .
Effects of BTM-0512 on the expression of brown/beige genes in adipose tissues of mice
The anti-obesity effects of BTM-0512 became more prominent after 6 weeks of treatment, therefore gene expressions were examined after 
PPARγ: peroxisome proliferator-activated receptor γ.
6 weeks of treatment. SIRT1 mRNA levels were reduced in SAT, BAT, and VAT of HFD mice, which was significantly increased by the administration of BTM-0512 or resveratrol (10 mg/kg intragastrically) for 6 weeks. Moreover, the effect of BTM-0512 on SIRT1 expression was stronger than that of resveratrol (Fig. 3) . In the BAT of HFD mice, UCP1 expression was down-regulated, but the expressions of other browning genes such as PRDM16 and CCAAT/enhancer binding protein beta (C/EBP-β) did not change. After treatment with BTM-0512 or resveratrol, the mRNA levels of total PRDM16 (tPRDM16), full length PRDM16 (fPRDM16), and UCP1 were increased (Fig. 3A) . In the SAT of HFD mice, the expressions of tPRDM16, fPRDM16, UCP1, and transmembrane protein 26 (TMEM26) were suppressed while resistin level was increased in the HFD group. These changes were reversed by BTM-0512 or resveratrol (Fig. 3B) . Moreover, after treatment with BTM-0512, up-regulation of UCP1 in SAT (up to 5-fold) seemed to be more prominent than that in BAT (~1.3-fold). In VAT of HFD mice, similar changes were observed for resistin and fPRDM16, but tPRDM16 mRNA (Fig. 3C) and protein ( Fig. 3D ) levels were not altered. BTM-0512 and resveratrol increased SIRT1 and tPRDM16 (Fig. 3C,D ) levels in visceral adipose, whereas the mRNA expressions of fPRDM16, UCP1, TMEM26, and CEBP-β were dramatically suppressed (Fig. 3C) .
Effects of BTM-0512 on beige gene expression in mouse preadipocytes
It has been reported that subcutaneous adipose is the major thermogenic adipose in adult humans or mice. Thus, the effects of BTM-0512 on mRNA expressions of UCP1, SIRT1, and PRDM16 were examined in undifferentiated preadipocytes or differentiated adipocytes obtained from SAT of male C57BL/6J mice. In undifferentiated subcutaneous preadipocytes, MTT assay showed that cell viability was not affected by BTM-0512 (0.1, 0.3, and 1 μM) or resveratrol (1, 3, and 10 μM) after treatment for 48 h (Fig. 4A) , or by BTM-0512 (1 μM) treatment for 24, 48, and 72 h (Fig. 4B) , respectively. Expressions of SIRT1 (Fig. 4C) , fPRDM16 (Fig. 4D) , and tPRDM16 (Fig. 4E ) mRNA were significantly increased by BTM-0512 (0.3 and 1 μM) and resveratrol (10 μM), while resveratrol at a concentration of 1 μM had no effects. SIRT1 antagonist nicotinamide (5 μM) reversed the effects of BTM-0512 (1 μM) on fPRDM16 (Fig. 4F) , tPRDM16 (Fig. 4G) , and UCP1 (Fig. 4H) . In differentiated subcutaneous adipocytes, the mRNA expressions of SIRT1 (Fig. 5A) , fPRDM16 (Fig. 5B) , tPRDM16 (Fig. 5C ), and UCP1 (Fig. 5D) , as well as UCP1 protein level (Fig. 6A) were up-regulated after treatment with BTM-0512 (1 μM) for 14 days, and these changes could be reversed by another specific SIRT1 antagonist, EX-527 (40 μM). In comparison with subcutaneous adipocytes, UCP1 protein level in cultured brown adipocytes seemed to be the highest among three types of adipose tissue (BAT, SAT, and VAT). No significant change was observed in either brown adipocytes (Fig. 6B ) or visceral adipocytes (Fig. 6C) after BTM-0512 (1 μM) treatment. These results suggested that BTM-0512 might participate in the regulation of beige remodeling of subcutaneous white preadipocytes via activation of SIRT1.
Over-expression of SIRT1 suppressed the beige remodeling genes in hVADSCs
As shown in Fig. 6C , the UCP1 protein level in adipogenicdifferentiated visceral adipocytes was barely detectable even after BTM-0512 treatment. Given that some SIRT1 agonists including resveratrol always show non-SIRT1-mediated effects (off-target effect), SIRT1 level was directly increased by transfecting hVADSCs (CD44 Fig. 7A ) with SIRT1-expressing construct (Fig. 7B) . Our results showed that SIRT1 significantly reduced lipid deposit (Fig. 7C) and resistin mRNA level (Fig. 7D) . Surprisingly, the mRNA expressions of TMEM26, UCP1, C/EBP-β, and fPRDM16 were also reduced by SIRT1 over-expression, while those of tPRDM16 and PPAR-γ were not affected by SIRT1 over-expression (Fig. 7D) .
Discussion
In the present study, we found that BTM-0512, a new SIRT1 agonist, exerted stronger anti-obesity effects than resveratrol (a typical SIRT1 activator) in HFD-induced obese mice. The expression of thermogenic gene UCP1 was significantly up-regulated in subcutaneous SAT, while it only showed moderate changes in BAT after BTM-0512 or resveratrol treatment. Our results also confirmed that BTM-0512 up-regulated PRDM16 and UCP1 expressions in subcutaneous preadipocytes/adipocytes via SIRT1 pathway. Strikingly, both animal and cell experiments indicated that SIRT1 could not promote beige remodeling in visceral adipocytes, accompanied by the reduction of fPRDM16 levels. Therefore, the major findings of our study are shown as follows: (i) new clues to search for potent SIRT1-targeting anti-obesity drugs; (ii) dramatic differential responses of visceral or subcutaneous preadipocytes to SIRT1 in the beige remodeling process; (iii) fPRDM16 level, compared with tPRDM16, appeared to be more closely associated with UCP1, partly accounting for SIRT1-mediated inhibition of beige remodeling in VAT (due to reduced fPRDM16 levels).
It is well known that SIRT1 might be a promising anti-obesity target via multiple mechanisms. As one of the largest endocrine organs, WAT has been widely investigated for its regulation of energy metabolism. A large number of studies revealed that SIRT1 participates in 'whiting process' of preadipocytes by regulating adipogenesis, lipolysis, and inflammation [22, 23] . Therefore, the development of SIRT1 agonists might be a new strategy in the therapy of obesity and related diseases. Compared with resveratrol, the novel SIRT1 agonist BTM-0512 is more fat-soluble and more stable. Our previous studies revealed that BTM-0512 has favorable effects on A B
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A BAT B SAT C VAT Figure 3 . Effects of BTM-0512 on gene expressions in adipose tissues in HFD-induced obese mice (A) The mRNA expressions of SIRT1, tPRDM16, fPRDM16, UCP1, and C/EBP-β in BAT; (B) the mRNA expressions of SIRT1, tPRDM16, fPRDM16, UCP1, TMEM26, and resistin in SAT; (C) the mRNA expressions of SIRT1, tPRDM16, fPRDM16, UCP1, TMEM26, and resistin in VAT; (D) the protein expressions of SIRT1 and tPRDM16 in VAT, after 6 weeks of treatment with resveratrol (10 mg/kg). (E) BAT, SAT, VAT from control C57BL/6J mice were stained by HE (400×). Con: control; HFD: high-fat diet-fed obese mice; +BTM: HFD mice treated with BTM-0512 (10 mg/kg); and +Res: HFD mice treated with resveratrol (10 mg/kg). Data were presented as the mean ± SD (n = 6 per group). *P < 0.05, **P < 0.01 vs. Con; # P < 0.05, ## P < 0.01 vs. HFD; and high glucose-induced endothelial cell dysfunction and senescence by up-regulating SIRT1 expression [24, 25] . In the present study, we demonstrated that BTM-0512 could significantly reduce body weight, Lee's index, visceral fat/body weight and blood glucose level, indicating a stronger anti-obesity effect than resveratrol. In consideration of the higher fat solubility of BTM-0512 than resveratrol, BTM-0512 might be more stable and easily concentrated in adipose tissue to regulate the differentiation of adipocytes [16, 17] , which might help to explain the stronger anti-obesity effects of BTM-0512 than resveratrol. But till now, the anti-obesity mechanisms of BTM-0512 still remain unknown. It has been shown that a high level of UCP1 in brown/beige adipose can enhance the uncoupling respiration and thermogenesis, beneficially reducing body weight and blood glucose [26, 27] . There are two types of brown adipocytes: classical brown adipocytes and inducible brown-like adipocytes (beige or brite cells). Most classical brown adipocytes are located in the neck and interscapular area, derived from myoblastic-like Myf5-positive precursors. Our results revealed that the UCP1 mRNA expression in interscapular brown adipose of HFD mice only increased moderately after BTM-0512 (10 mg/kg intragastrically) treatment. Similar results were obtained in cultured brown adipocytes from C57BL/6J mice. Although basal UCP1 protein level seemed to be higher in brown adipocytes than that in white adipocytes, the UCP1 protein levels in BAT were indistinguishable between the control group and the BTM-0512 (1 μM)-treated group. The exact reasons, albeit partly attributable to drug concentrations and/or culture condition, remain to be fully delineated in future investigations. In this study, we did not use beige differentiation medium, in order to exclude the influence of some commonly used strong beige stimulus, such as T3 or β adrenergic agonists.
Recently, studies have demonstrated that beige adipose, rather than the brown adipose, is the major thermogenic fat in adults [28] . Beige adipocytes are derived from a non-Myf5 cell lineage (e.g. adipose-derived stem cell) with some specific cell markers detectable in WAT of adult animals after exposure to cold or adrenergic agonists, such as TMEM26, CD137, and T-box transcription factor [29, 30] . Recent studies have also demonstrated that over-expression of SIRT1 results in down-regulation of WAT-specific genes and upregulation of beige characteristics in mouse subcutaneous WAT via recruitment of PRDM16 [9] . In the present study, we found that BTM-0512 could significantly up-regulate UCP1 expression in subcutaneous adipose of HFD mice. In cultured subcutaneous white preadipocytes, UCP1 levels were significantly elevated by BTM-0512 under undifferentiation or differentiation conditions, which was reversable by SIRT1 antagonist NAM or EX-527. These results indicate that BTM-0512 ameliorates obesity by promoting beige remodeling in SAT via SIRT1 pathway.
VAT and SAT are suggested to have diverse origins and biological characteristics. Visceral adiposity (central obesity) is more closely correlated with metabolic and cardiovascular disorders than subcutaneous adiposity (peripheral obesity) [31] [32] [33] [34] . A recent clinical study demonstrates that the expression of SIRT1 mRNA in VAT and SAT is suppressed in obesity and Type 2 diabetic women, inversely correlated with obesity and insulin resistance-related parameters. Moreover, SIRT1 mRNA level in VAT is related to visceral obesity, but that in SAT is correlated closely with body mass index (BMI) [35] . In the present study, animal experiment showed that SIRT1 agonists not only caused weight loss, but also decreased the ratio of visceral fat/body weight in the HFD group. But it is unclear whether this effect is associated with beige remodeling of visceral preadipocytes. Surprisingly, no comparable promotion of beige remodeling by BTM-0512 was observed in VAT as that in SAT. On the contrary, beige genes in the HFD group, including UCP1, TMEM26, and C/EBP-β, were down-regulated after resveratrol or BTM-0512 treatment. In cultured visceral adipocytes from C57BL/6J mice, we also found that BTM-0512, at a concentration of 1 μM, could not up-regulate the expression of UCP1. Since higher dose of BTM-0512 might cause toxicity to cultured cells, elevation of BTM-0512 dose was not the best option to eliminate the possible deviation. Thus, we performed SIRT1 over-expression in hVADSCs and found that beige genes were also down-regulated by SIRT1 over-expression. These data further substantiated our hypothesis that the reduction of visceral adiposity caused by BTM-0512 at the applied doses was not associated with beige remodeling of visceral preadipocytes. However, the questions of why SIRT1 agonists cannot promote beige remodeling in VAT, and how BTM-0512 reduces visceral adipose remain to be addressed.
To explore why SIRT1 agonists cannot promote beige remodeling in VAT, we examined different alternative splicing isoforms of PRDM16 mRNA. As is well known, PR domain-containing 16 (PRDM16) gene is a zinc finger protein in PRDM family. It consists of a PR domain and a 134-amino acid region with high homology to the SET domain. Recent studies showed that PRDM16 can regulate the thermogenic genes (e.g. UCP1) and overexpression of PRDM16 promotes brown/beige remodeling of multiple precursors, such as white preadipocytes and myoblasts, whereas ablation of PRDM16 and beige adipose can cause metabolic dysfunction [36] [37] [38] . It has been reported that there are several PRDM16 isoforms after mRNA alternative splicing, including full length PRDM16 (fPRDM16) and short length PRDM16 (sPRDM16, lack of PR domain). fPRDM16 and sPRDM16 have different functions in the development of acute myeloid leukemia [21] , indicating that different PRDM16 isoforms might play distinct roles in certain biological processes. Interestingly, we observed that changes in fPRDM16 and tPRDM16 (fPRDM16 + sPRDM16) levels in VAT were distinct from those in SAT. In SAT, SIRT1 increased both fPRDM16 and tPRDM16 levels, concomitant with the up-regulation of UCP1. But in VAT, SIRT1 reduced fPRDM16 and UCP1 levels, while the tPRDM16 level was not altered. Due to these unaddressed issues, more studies are needed. Real-time PCR was performed to examine the mRNA expressions of tPRDM16, fPRDM16, PPAR-γ, C/EBP-β, UCP1, TMEM26, and resistin. Con: cells were transfected with the empty plasmid; SIRT-T: cells were transfected with a plasmid containing the SIRT1 gene. Data were presented as the mean ± SD (n = 3 per group). *P < 0.05, and **P < 0.01 vs. Con.
To address how BTM-0512 reduces visceral adipose, we examined the expression of resistin. It has been proved that insulin resistance and inflammation contribute to the overall phenotype of visceral adiposity syndrome [39] . Resistin is a white adiposity-related adipokine, which is involved in the development of obesity and insulin resistance. There is a significant BMI-dependent association between resistin and insulin resistance in patients with T2DM [40] . In 3T3-L1 cells, resistin affects glucose uptake and promotes adipogenesis [41] , and resveratrol reduces resistin expression in mature 3T3-L1 adipocytes as well as in primary mouse embryonic fibroblasts, resulting in enhanced fatty acid oxidation capacity and reduced lipogenesis [42] . Recent studies revealed that resveratrol could inhibit visceral adiposity by attenuating inflammation and insulin resistance in VAT [43] . In the present study, we observed that resistin expressions in both subcutaneous and visceral adipose were up-regulated by HFD, and BTM-0512 could notably down-regulate it in SAT or VAT. When SIRT1 was over-expressed in hVADSCs, lipid deposit was reduced, which was accompanied by a decrease in resistin expression. Those results indicate an involvement of resistin in the inhibition of visceral adiposity after BTM-0512 treatment. Moreover, a recent study also revealed that ablation of PRDM16 and beige adipose can cause metabolic dysfunction and a subcutaneous to visceral fat switch [38] , suggesting that the effect of BTM-0512 on beige remodeling of SAT might affect visceral adiposity. It might be an interesting project for future study.
It should be noted that there are still some limitations in this study. First, the obese mice seemed to gain much less body weight than usual. A possible explanation for this phenomenon might be the extremely high cholesterol (2%) contained-HFD used in this study. Although high cholesterol contained-HFD was also used by other researchers [44, 45] , the discrepancy caused by different HFD models should be taken into account in our future study. Second, we failed to provide the data for SAT or BAT index, although the effect of SIRT1 on SAT or BAT formation has been reported [9, 14] . Third, the protein expression or activation of SIRT1 and PRDM16 should be examined, although SIRT1 antagonists NAM and EX-527 were used to confirm the role of SIRT1 in mediating the effects of BTM-0512.
In summary, we demonstrated that BTM-0512 could promote beige remodeling in SAT, exerting stronger anti-obesity effects than resveratrol. In contrast, high levels of SIRT1 could not promote beige remodeling of VAT, and the accompanied reduction of fPRDM16 level indicated that maintaining high levels of fPRDM16 might be more important in white/beige switch than solely elevating tPRDM16 level.
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